These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6056372)

  • 21. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
    Schwemer WL; Lynch MA
    J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
    [No Abstract]   [Full Text] [Related]  

  • 22. Quality control and good manufacturing practices: safety and efficacy of commercial herbals.
    Awang DV
    Food Drug Law J; 1997; 52(3):341-4. PubMed ID: 10343036
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharmacotherapy between theory and practice].
    Stricker BH
    Ned Tijdschr Geneeskd; 1995 Nov; 139(45):2295-6. PubMed ID: 7501059
    [No Abstract]   [Full Text] [Related]  

  • 24. Manufacturing misdeeds cost Abbott record-breaking payment.
    Lewis C
    FDA Consum; 2000; 34(3):38-9. PubMed ID: 11521253
    [No Abstract]   [Full Text] [Related]  

  • 25. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 1999; 885():i-vi, 1-156. PubMed ID: 10352573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Panel discussion: in process control and inspection for quality assurance. I.
    Shea JJ
    Bull Parenter Drug Assoc; 1968; 22(2):82-7. PubMed ID: 5649570
    [No Abstract]   [Full Text] [Related]  

  • 27. Botanical drugs: a future for herbal medicines.
    Li W
    J Contemp Health Law Policy; 2002; 19(1):117-49. PubMed ID: 12733224
    [No Abstract]   [Full Text] [Related]  

  • 28. Parenteral manufacturing standards in Canada.
    Dunford RA
    Bull Parenter Drug Assoc; 1968; 22(5):209-14. PubMed ID: 5678806
    [No Abstract]   [Full Text] [Related]  

  • 29. [Guidelines for introducing new drugs for medical use in Poland and control of their quality].
    Danysz A
    Pol Tyg Lek; 1984 Dec 17-31; 39(51-52):1673-4. PubMed ID: 6522321
    [No Abstract]   [Full Text] [Related]  

  • 30. Panel discussion: in process control and inspection for quality assurance. 3.
    Brofazi FR
    Bull Parenter Drug Assoc; 1968; 22(2):90-6. PubMed ID: 5649572
    [No Abstract]   [Full Text] [Related]  

  • 31. Selection of raw materials.
    McGilveray IJ
    Med Serv J Can; 1967 Mar; 23(3):233-51. PubMed ID: 6056369
    [No Abstract]   [Full Text] [Related]  

  • 32. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 33. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug development history, "overview," and what are GCPs?
    Heilman RD
    Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Counterfeiting and piracy of pharmaceuticals.
    Grackin A
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract]   [Full Text] [Related]  

  • 36. Panel discussion: in process control and inspection for quality assurance. II.
    Hofer AJ
    Bull Parenter Drug Assoc; 1968; 22(2):87-90. PubMed ID: 5649571
    [No Abstract]   [Full Text] [Related]  

  • 37. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 38. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparing for an FDA preapproval inspection.
    Blackmer RA
    Qual Assur; 1994 Dec; 3(4):389-403. PubMed ID: 7613749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Counterfeit and substandard drugs.
    Reidenberg MM; Conner BA
    Clin Pharmacol Ther; 2001 Apr; 69(4):189-93. PubMed ID: 11309546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.